Raymond James analyst Danielle Brill raised the firm’s price target on Disc Medicine to $43 from $40 and keeps an Outperform rating on the shares. Raymond James remains optimistic on the outlook for Disc Medicine and sees upside potential from positive FDA feedback on the path forward for bitopertin later this year, along with upcoming Q2 catalysts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine reports Q1 EPS ($1.09), consensus ($1.00)
- Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
- Disc Medicine price target raised to $73 from $71 at Stifel
- Disc Medicine’s Bitopertin Shows Promise in EPP Study
- Disc Medicine price target lowered to $50 from $80 at BMO Capital
Questions or Comments about the article? Write to editor@tipranks.com